Arbutus biopharma corp (ABUS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue
Collaborations and contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,021

8,299

11,712

12,192

12,735

11,569

11,738

10,899

10,282

11,982

10,425

0

0

0

Licensing fees, milestone and royalty payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,045

10,898

11,564

4,345

4,099

3,636

3,215

2,194

0

0

-

0

-

-

Revenue

6,823

6,011

6,071

4,597

5,188

5,945

6,801

12,106

11,901

10,700

7,971

1,853

1,123

1,491

12,775

16,066

19,197

23,276

16,537

16,834

15,205

14,953

18,129

16,730

17,763

15,465

0

0

0

Non-cash royalty revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Non-cash royalty revenue
Research and development

53,305

57,601

56,246

55,081

58,697

57,934

64,693

63,664

62,753

62,676

62,010

62,211

61,981

61,253

59,001

59,617

54,092

51,505

48,503

41,458

41,066

38,713

33,782

29,979

25,595

21,458

0

0

0

General and administrative

16,868

17,727

21,777

21,159

16,745

16,002

13,618

14,646

15,470

16,129

17,319

17,380

36,547

39,438

43,059

47,045

30,941

26,438

21,166

15,224

9,349

8,683

8,445

7,641

6,703

5,546

0

0

0

Depreciation

2,019

2,028

2,025

2,015

2,088

2,181

2,297

2,393

2,295

2,027

1,739

1,437

1,209

1,092

929

791

686

589

533

513

515

529

563

578

581

613

0

0

0

Gain on disposition of financial instrument

-

-

-

-

-

-

-

-

-

-

-

-

-

1,000

1,000

1,000

1,000

0

0

0

0

-

-

-

-

-

-

-

-

Foreign exchange gains (losses)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Fair Value, Option, Changes in Fair Value, Gain (Loss)

-

-

-

-

-

-

-

-

-

-22

169

179

347

530

903

2,869

4,725

3,341

5,337

-1,779

2,010

-10,383

-14,318

-11,613

-17,454

-3,530

0

0

0

Change in fair value of contingent consideration

-186

-173

-1,156

-6,388

-6,325

-7,298

-6,050

-245

-548

1,359

1,958

2,021

2,383

1,568

1,526

1,266

1,014

770

0

0

0

-

-

-

-

-

-

-

-

Site consolidation

96

156

1,120

446

3,293

4,797

3,710

4,202

1,621

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,656

9,656

9,656

0

-

0

0

-

-

-

-

-

Impairment of Intangible Assets (Excluding Goodwill)

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

0

-

-

0

0

-

-

0

-

-

-

-

-

-

Impairment of goodwill

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss Contingency, Loss in Period

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

144,848

150,085

154,086

93,637

95,759

95,725

139,927

125,703

122,937

121,630

316,091

316,051

491,084

493,130

260,330

302,784

125,087

127,195

118,310

67,313

60,687

48,387

42,790

38,198

32,879

27,617

0

0

0

Total operating expenses

-138,025

-144,074

-148,015

-89,040

-90,571

-89,780

-133,126

-113,597

-111,036

-110,930

-308,120

-314,198

-489,961

-491,639

-247,555

-286,718

-105,890

-103,919

-101,773

-50,479

-45,482

-33,434

-24,661

-21,468

-15,116

-12,152

0

0

0

Loss from operations
Interest income

1,856

2,111

2,437

2,690

2,889

3,047

2,762

2,343

1,928

1,538

1,382

1,470

1,515

1,391

1,312

1,070

716

674

611

732

908

853

828

653

542

540

0

0

0

Interest expense

3,137

2,108

1,236

136

134

226

179

255

323

261

186

110

42

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Foreign exchange (losses) / gains

15

41

-220

-50

-469

-1,003

-897

191

1,348

2,301

1,398

-630

-1,395

1,120

7,683

20,279

17,675

21,771

19,344

0

0

-

0

-

2,527

1,079

0

0

0

Gain (Loss) on Investments

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net equity investment loss

0

-

-14,221

-13,547

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other loss

-18,964

-22,305

-11,959

-4,530

23,407

28,438

29,782

27,408

3,501

2,197

805

-1,112

-1,958

2,473

9,372

23,952

23,102

25,016

17,751

0

0

-

0

-

-

-

-

-

-

Loss before income taxes

-156,989

-166,379

-170,480

-72,230

0

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

0

-

-

-

-

-

-

Income tax benefit

0

-

0

-

0

-

0

-

-

-

0

-

-

-

0

0

-

-

0

0

-

-

0

-

-

-

-

-

-

Net Income (Loss) Attributable to Parent

0

-

0

-

0

-

0

-

-83,215

-84,413

-267,177

-275,172

-386,917

-384,164

-172,330

-181,717

-66,603

-62,718

-62,025

-41,647

-32,842

-38,837

-35,267

-32,568

-29,501

-14,063

0

0

0

Items applicable to preferred shares:
Dividend accretion of convertible preferred shares

11,412

11,149

10,916

10,691

10,470

10,091

8,355

5,788

3,247

911

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shares

-155,745

-164,872

-158,234

-99,979

-73,352

-67,151

-83,097

-67,657

-86,462

-85,324

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in USD per share)

-

-

-

-0.46

-

-

-

0.01

-

-

-

-0.33

-

-

-

-

-

-

-

-

-

-

-

-

-0.91

-

-

-

-

Diluted (in USD per share)

-

-

-

-0.46

-

-

-

0.01

-

-

-

-0.33

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and dilutive (in USD per share)

-0.25

-

-1.50

-

-0.47

-

-0.49

-

-0.36

-

-0.21

-

-0.34

-

-0.37

-2.47

-0.31

-

-0.57

-0.27

-0.40

-

-0.39

-0.28

-

-

-0.41

-0.21

-0.18

Net loss per common share
Basic (in shares)

-

-

-

56,805

-

-

-

55,211

-

-

-

54,647

-

-

-

-

-

-

-

-

-

-

-

-

19,801

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

-

56,805

-

-

-

56,487

-

-

-

54,647

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

67,683

-

56,850

-

55,740

-

55,421

-

55,071

-

54,877

-

54,307

-

53,652

52,716

51,400

-

50,756

54,255

30,208

-

22,159

22,063

-

-

14,511

14,406

14,344

Unrealized gain on available-for-sale securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive income
Currency translation adjustment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-25,872

-19,329

-14,055

-13,504

-6,489

-4,945

592

-4,418

-3,135

0

0

0

Comprehensive loss

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-88,590

-81,354

-55,702

-46,346

-45,326

-40,212

-31,976

-33,919

-17,198

0

0

0

Collaboration And Contracts [Member]
Revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-